Industries > Pharma > Global Acute Myeloid Leukaemia Market Forecast to 2029

Back to Pharma Reports

Global Acute Myeloid Leukaemia Market Forecast to 2029

Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib

PUBLISHED: 31 October 2019

PAGES: 149

PRODUCT CODE: PHA0576

SUBMARKET: Therapeutic Drugs

SKU: PHA0576 Categories: Pharma, Therapeutic Drugs Tags: PHA0576, PHA0621

The global acute myeloid leukaemia market is estimated to grow at a CAGR of 13% in the first half of the forecast period. In 2018, the chemotherapy segment held 32% share of the global acute myeloid leukaemia market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 149-page report you will receive 143 charts– all unavailable elsewhere.

The 149-page report provides clear detailed insight into the acute myeloid leukaemia market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Acute Myeloid Leukaemia Market forecast to 2029

• Forecast of the Global Acute Myeloid Leukaemia market by Treatment Type and Product Type:
• Chemotherapy: Cytarabine, Daunorubicin, Others
• Targeted Therapy: Midostaurin, Enasidenib, Others

• This report provides individual revenue forecasts to 2029 for these regional and national markets:
• North America: US, Canada, and Mexico
• Europe: Germany, France, United Kingdom, Italy, Spain and rest of Europe
• Asia-Pacific: Japan, China, India, Australia and Rest of Asia-Pacific
• LAMEA: GCC, Brazil, South Africa, Rest of LAMEA

Each national market forecast is further segmented by type: chemotherapy and targeted therapy.

• Our study discusses the selected leading companies that are the major players in the acute myeloid leukaemia market:
• Bristol-Myers Squibb Company
• Celgene
• Clavis Pharma ASA
• Daiichi Sankyo
• Eisai
• GSK
• Novartis
• Roche
• Sunesis Pharmaceuticals
• Teva

• This report discusses factors that drive and restrain the acute myeloid leukaemia market. This report also discusses the opportunities that can be tapped in this market.

• This report discusses Porter’s Five Forces analysis of the acute myeloid leukaemia market.

• This report also discusses several new agents that are in development for the treatment of acute myeloid leukaemia.

• Key questions answered in this report:
• How is the Acute myeloid leukemia market evolving?
• What are the drivers and restraints for the growth of the acute myeloid leukemia market?
• What are the market shares of each segment of the overall acute myeloid leukemia market in 2019?
• How will each acute myeloid leukemia submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2029?
• How will the market shares for each acute myeloid leukemia submarket develop from 2019 to 2029?
• What is the value of the leading acute myeloid leukemia segments in important regions of the world?
• What will be the main driver for the overall market from 2019 to 2029?
• How will political and regulatory factors influence the regional markets and submarkets?
• How will the market shares of the national markets change by 2029 and which geographical region will lead the market by 2029?
• Who are the leading players and what are their prospects over the forecast period?
• How will the industry evolve during the period between 2019 and 2029?

Visiongain’s study is intended for anyone requiring commercial analyses for the acute myeloid leukaemia market. You find data, trends and predictions.

Buy our report today Acute Myeloid Leukaemia Market Analysis : Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

1. Report Overview

1.1 Global Leukemia Market Overview

1.2 Market Definition and Scope

1.3 Why you should read this report?

1.4 How the report delivers?

1.5 Key Questions Answered in this Report

1.6 Who is the report for?

1.7 Report and Analysis Method

1.8 Frequently Asked Questions

1.9 Some Associated Reports

1.10 About Visiongain

2. Acute Myeloid Leukemia Market Overview

2.1 Introduction

2.1.1 French-American-British (FAB) classification

2.1.2 WHO Classification of AML

2.2 Epidemiology of AML

2.3 Treatment for AML

2.3.1 Medication Overview

3. Global Acute Myeloid Leukemia Market Forecast to 2029 – Based on Drug Type

3.1 Chemotherapy Based AML Therapeutics Market, 2019-2029

3.1.1 Cytarabine

3.1.2 Daunorubicin

3.1.3 Other Chemotherapy Drugs

3.2 Targeted therapy Market for AML Therapeutics – 2019-2029

3.2.1 Midostaurin

3.2.2 Enasidenib

3.2.3 Other targeted therapy

3.3 Other drugs used in the treatment of AML

4. Global AML Therapeutics Market Forecast to 2029 – Regional and National Market

4.1 North America AML Therapeutics Market Forecast, 2019-2029

4.1.1 USA AML Therapeutic Market Forecast, 2019-2029

4.1.2 Canada AML Therapeutic Market Forecast, 2019-2029

4.1.3 Mexico AML Therapeutic Market Forecast, 2019-2029

4.2 Europe AML Therapeutics Market Forecast, 2019-2029

4.2.1 Germany AML Therapeutics Market Forecast, 2019-2029

4.2.2 UK AML Therapeutics Market Forecast, 2019-2029

4.2.3 Italy AML therapeutics Market Forecast, 2019-2029

4.2.4 France AML Therapeutics Market Forecast, 2019-2029

4.2.5 Spain AML Therapeutics Market, 2019-2029

4.2.6 Rest of Europe AML Therapeutics Market Forecast, 2019-2029

4.3 Asia Pacific AML Therapeutics Market Forecast, 2019-2029

4.3.1 Japan AML Therapeutics Market Forecast, 2019-2029

4.3.2 China AML Therapeutics Market Forecast, 2019-2029

4.3.3 India AML Therapeutics Market Forecast, 2019-2029

4.3.4 Australia AML Therapeutics Market Forecast, 2019-2029

4.3.5 Rest of Asia Pacific AML Therapeutic Market Forecast, 2019-2029

4.4 Latin America and Middle East Africa AML Therapeutics Market Forecast, 2019-2029

4.4.1 GCC AML Therapeutics Market Forecast, 2019-2029

4.4.2 Brazil AML Therapeutics Market Forecast, 2019-2029

4.4.3 South Africa AML Therapeutics Market Forecast, 2019-2029

4.4.4 Rest of LAMEA AML Therapeutics Market, 2019-2029

5. Company Profiles

5.1 Daiichi Sankyo

5.1.1 Company Overview

5.1.2 Financial Overview

5.1.3 Recent Strategic Developments

5.2 Celgene Corporation

5.2.1 Company Overview

5.2.2 Operational Segments

5.2.3 Financial Overview

5.2.4 Recent Developments

5.3 Teva Pharmaceuticals

5.3.1 Company Profile

5.3.2 Operational Segments

5.3.3 Financial Highlights

5.3.4 Recent Developments

5.4 Eisai., Co. Ltd.

5.4.1 Company Overview

5.4.2 Operational Segments

5.4.3 Financial Overview

5.5 Novartis AG

5.5.1 Company Profile

5.5.2 Operational Segments

5.5.3 Financial Highlights

5.5.4 Recent Developments

5.6 GlaxoSmithKline Inc

5.6.1 Company Overview

5.6.2 Operating Segments

5.6.3 Financial Highlights

5.7 Sunesis Pharmaceuticals

5.7.1 Company Profile

5.7.2 Operational Segments

5.7.3 Financial Overview

5.8 Clavis Pharma ASA

5.8.1 Company Profile

5.9 F. Hoffman-La Roche Ltd.

5.9.1 Company Profile

5.9.2 Operational Segments

5.9.3 Financial Analysis

5.9.4 Recent Strategic Development

5.10 Bristol-Myers Squibb

5.10.1 Company Profile

5.10.2 Financial Overview

6. Acute Myeloid Leukemia: Qualitative Analysis

6.1. Market Drivers

6.1.1 The rise in Cases of Chronic Diseases

6.1.2 Research for Innovative Therapeutics

6.1.3 Increase in the geriatric population

6.2 Market Restraints

6.2.1 The adverse effect of the treatment

6.3 Market Opportunities

6.3.1 Unmet Oncological Demand

6.3.2 Untapped Opportunities in developing countries

7. Industry Analysis of the Market Players (Porter’s Five Force Analysis)

7.1 Bargaining Power of Suppliers

7.2 The threat of New Entrants

7.3 The threat of Substitute for Product

7.4 Bargaining Power of Buyers

7.5 Bargaining Power of Suppliers

8. Pipeline and Clinical trial Analysis

8.1 Pipeline Analysis

8.1.1 Vosaroxin (Sunesis Pharmaceuticals)

8.1.2 CPX-351 (Celator Pharmaceuticals)

8.1.3 Sepacitabine (Cyclacel)

8.1.4 SGI-110 (Astex)

8.2 Small Molecule Targeted Therapy

8.2.1 Volasertib (Boehringer Ingelheim)

8.3 Isocitrate Dehydrogenase Inhibitor

8.3.1 ABT -199s (AbbVie, Roche)

8.3.2 FLT3 Inhibitors

8.3.3 Sorafenib (Bayer, Onyx Pharmaceuticals)

8.3.4 Midostaurin (Novartis)

8.3.5 Quizartinib (Daiichi Sankyo)

8.4 Monoclonal Antibodies

8.4.1 SGN-33A (Seattle Genetics)

8.4.2 AMG-330 (Amgen)

8.5 Clinical Trials

9. Conclusion

Appendices

Associated Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain Report Evaluation Form

List of Tables

Table 2.1 Global Acute Myeloid Leukemia, Subtypes, Based on FAB Classification

Table 2.2 Global Acute Myeloid Leukemia, Subtypes, Based on WHO Classification

Table 3.1. Global Acute Myeloid Leukemia Therapeutic Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 3.2. Global AML Therapeutics Market – Based on type (in %), 2018-2029

Table 3.3 Global AML Chemotherapy Drug Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 3.4. Cytarabine Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 3.5 Daunorubicin Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 3.6. Other Chemotherapy Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 3.7 Targeted Therapy Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 3.8 Midostaurin Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 3.9 Enasidenib Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 3.10 Other Targeted Therapy Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.1. North America AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Like the global perspective, the North American Chemotherapy market is expected to show a higher market share as compared to the Targetearket.

Table 4.2 North America AML therapeutics Drug Market by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.3. USA AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.4. USA AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029

Table 4.5. USA AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.6. Canada AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.7. Canada AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.8. Mexico AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.9. Mexico AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.10. Europe AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.11. Europe AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.12 Germany AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.13 Germany AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.14 UK AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.15 UK AML Therapeutics Market by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.16 Italy AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.17. Italy AML Therapeutics Market Forecast by Type Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.18 France AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.19. France AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.20. Spain AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.21. Spain AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.22. Rest of Europe AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.23. ROE AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.24. Asia Pacific AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.25. Asia Pacific AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.26. Japan AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.27. Japan AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.28. China AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.29. China AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.30. India AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.31. India AML Therapeutics Market Forecast by Type: (Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.32. Australia AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.33. Australia AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.34. Rest of Asia Pacific AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.35. Rest of Asia Pacific AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.36. LAMEA AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.37. LAMEA AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.38. GCC AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.39. GCC AML Therapeutics Market by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.40. Brazil AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.41. Brazil AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.42. South Africa AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.43. South Africa AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.44. Rest of LAMEA AML Therapeutics Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 4.45. Rest of LAMEA AML Therapeutics Market Forecast by Type: Revenue ($m), AGR (%), CAGR (%), 2019-2029

Table 5.1 Daiichi Sankyo: Revenue ($m), R&D ($m), 2016-2018

Table 5.2 Daiichi Sankyo Recent Developments

Table 5.3 Celgene: Revenue ($m), R&D ($m), 2016-2018

Table 5.4 Celgene Recent Developments

Table 5.5 TEVA Operating Segments

Table 5.6 TEVA: Revenue ($m), R&D ($m), 2016-2018

Table 5.7 TEVA Recent Developments

Table 5.8 Eisai Operating Segments

Table 5.9 Eisai Revenue ($m), R&D ($m), 2016-2018

Table 5.10 Novartis Operating Segments

Table 5.11 Novartis: Revenue ($m), R&D ($m), 2016-2018

Table 5.12 Novartis Recent Developments

Table 5.13 GSK Operating Segments

Table 5.14 GSK: Revenue ($m), R&D ($m), 2016-2018

Table 5.15 Sunesis: Revenue ($m), R&D ($m), 2016-2018

Table 5.16 Roche Operating Segments

Table 5.17 Roche: Revenue ($m), R&D ($m), 2016-2018

Table 5.18 Roche Recent Developments

Table 5.19 Bristol-Myers: Revenue ($m), 2016-2018

Table 8.1 AML Drugs in the Pipeline: Agent, MOA, Clinical Trial Code

Table 8.2 Completed Clinical Trials for AML

Table 8.3 List of Recruiting Clinical Trials for AML

Table 9.1: Global Acute Myeloid Leukemia Market by Treatment Type: Revenue ($m), 2019, 2023, 2029

List of Figures

Figure 2.1 Percentage of estimated new Leukemia cases in 2018 among all blood cancer cases, a global perspective

Figure 2.2 Prevalence of Acute Myeloid Leukemia in the population based on age (2018)

Figure 3.1. Global Acute Myeloid Leukemia Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 3.2. Global AML Therapeutics Market (% Share) – Based on Type, 2018

Figure 3.3 Global AML Chemotherapy Drug Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 3.4. Global AML Chemotherapy Drugs (% Share) – Based on types 2018

Figure 3.5. Cytarabine Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 3.6 Daunorubicin Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 3.7. Other Chemotherapy Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 3.8. Targeted Therapy Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 3.9. Midostaurin Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 3.10 Enasidenib Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 3.11 Other Targeted Therapy Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 4.1. Global Percentage Share of AML Therapeutics Market by Region: % Share, 2019

Figure 4.2. Global Percentage Share of AML Therapeutics Market by Region: % Share, 2023

Figure 4.3. Global Percentage Share of AML Therapeutics Market by Region: % Share, 2029

Figure 4.4. North America AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 4.5 North America AML Therapeutics Market by Country: % Share, 2019

Figure 4.6. USA AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029

Figure 4.7. Canada AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 4.8. Canada AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029

Figure 4.9. Mexico AML therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 4.10 Mexico AML therapeutic Market Forecast by Type: Revenue ($m), 2019-2029

Figure 4.11. Europe AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 4.12. Europe AML Therapeutics Market by Region: % Share, 2019

Figure 4.13. Germany AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 4.14 Germany AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029

Figure 4.15. UK AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 4.16 UK AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029

Figure 4.17. Italy AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 4.18. Italy AML Therapeutics Market Forecast: Revenue ($m), 2019-2029

Figure 4.19 France AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 4.20. France AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029

Figure 4.21 Spain AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 4.22. Spain AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029

Figure 4.23. Rest of Europe AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 4.24. ROE AML Therapeutics Market by Type: Revenue ($m), 2019-2029

Figure 4.25. Asia Pacific AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 4.26. Asia Pacific AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029

Figure 4.27. Asia Pacific AML Therapeutics Market by Country: % Share, 2019

Figure 4.28. Japan AML therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 4.29. Japan AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029

Figure 4.30. China AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 4.31. China AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029

Figure 4.32. India AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 4.33. India AML Therapeutics Market by Type: Revenue ($m), 2019-2029

Figure 4.34. Australia AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 4.35. Australia AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029

Figure 4.36. Rest of Asia Pacific AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 4.37. Rest of Asia Pacific AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029

Figure 4.38. LAMEA AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 4.39. LAMEA AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029

Figure 4.40 LAMEA AML Therapeutics Market by Country: % Share, 2019

Figure 4.41. GCC AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 4.42. GCC AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029

Figure 4.43 Brazil AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 4.44. Brazil AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029

Figure 4.45. South Africa AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 4.46. South Africa AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029

Figure 4.47. Rest of LAMEA AML Therapeutics Market Forecast: Revenue ($m), AGR (%), 2019-2029

Figure 4.48. Rest of LAMEA AML Therapeutics Market Forecast by Type: Revenue ($m), 2019-2029

Figure 9.1: Global Acute Myeloid Leukemia Market by Treatment Type: Revenue ($m), 2019, 2023, 2029

AbbVie

Agios Pharmaceuticals, Inc.

Ambit Biosciences Corporation

Amgen

Animas Corporation

Astex

B. Braun Melsungen AG

Baxter, Becton, Dickinson and Company (BD)

Bayer

Boehringer Ingelheim

Bristol-Myers Squibb Company (Bristol-Myers)

Celator Pharmaceuticals, Inc.

Celgene

Clavis Pharma ASA (Clavis Pharma)

Cyclacel

Daiichi Pharmaceutical

Daiichi Sankyo

Eisai Co., Ltd. (Eisai)

F. Hoffmann-La Roche Ltd. (Roche)

Fresenius SE & Co. KGaA

GlaxoSmithKline plc (GSK)

GLOBOCAN

Hospira

Medtronic

Moog Inc.

NeoMed

Norsk Hydro

Novartis

Onyx Pharmaceuticals

Sankyo

Seattle Genetics

Smiths Group Plc.,

Sunesis Pharmaceuticals, Inc. (Sunesis)

TEVA Pharmaceutical Industries Limited (TEVA)

List of Organizations Mentioned in the Report

American Cancer Organization

Baylor Scott and White Research Institute

Benaroya Research Institute at Virginia Mason

Beth Israel Deaconess Medical Center

Breslin Cancer Center

Center for Blood Disorders and Stem Cell Transplantation

Charles A. Sammons Cancer Center

Columbia University Medical

Dana Farber Cancer Institute

Duke Cancer Center

European Commission

Fred Hutchinson Cancer Research Center

Health Canada

Herbert Irving Comprehensive Cancer Center

Institute of Hematology & Blood Diseases Hospital,Tianjin

James Graham Brown Cancer Center

Legacy Emanuel Hospital & Health Center

Mary Babb Randolph Cancer Center

Massachusetts general Hospital

Mayo Clinic

MD Anderson Cancer Center

Medical College of Wisconsin Cancer Center

Medizinische Klinik und Poliklinik I

Memorial Sloan Kettering Cancer Center

Michigan State University

Nantes University Hospital

National Cancer Institute

New Jersey Hematology Oncology Associates

Northwestern University

Ochsner Medical Center

Penn State Hershey Cancer Institute-Clinical Trials Office

Perelman Center for Advanced Medicine

Princess Margaret Hospital

St. Francis Cancer Center

St. Joseph Mercy Hospital

St. Vincent's Comprehensive Cancer Center

Swedish Cancer Institute

The Gayle and Tom Benson Cancer Center

The University of Hong Kong

The University of Iowa

The University of Texas MD Anderson Cancer Center

Thomas Jefferson University

U.S. Food and Drug Administration (FDA)

UCLA Medical Center, Division of Hematology/Oncology

University Hospital, Caen

University of Kansas Cancer Center

University of Kansas Medical Center Research Institute

University of Kentucky

University of Louisville

University of Michigan Health System

University of Pennsylvania

University of Texas M.D. Anderson Cancer Center

VA Caribbean Healthcare System

Weill Cornell Medical College

Weill Medical College of Cornell University

West Virginia University

World Health Organization (WHO)

Download sample pages

Complete the form below to download your free sample pages for Global Acute Myeloid Leukaemia Market Forecast to 2029

Download sample pages

Complete the form below to download your free sample pages for Global Acute Myeloid Leukaemia Market Forecast to 2029

Case studies

Need customized work?

Report overview

Methodology

Client testimonials

Pharmaceutical industry associations

American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia

Connect with us

Visiongain Pharma

Latest Pharma news

Visiongain Publishes Precision Medicine Market Report 2022-2032

The global precision medicine market was valued at US$63,333 million in 2021 and is projected to grow at a CAGR of 10.8% during the forecast period 2022-2032.

05 July 2022

READ

Visiongain Publishes Biologics Market Report 2022-2032

The global biologics market was valued at US$382.85 billion in 2022 and is projected to grow at a CAGR of 8.82% during the forecast period 2022-2032.

04 July 2022

READ

Visiongain Publishes Liposomal Drug Delivery Devices Market Report 2022-2032

Global liposomal drug delivery devices market is projected to grow at a CAGR of 10.69% by 2032.

21 June 2022

READ

Visiongain Publishes Nanotechnology in Drug Delivery Market Report 2022-2032

The global nanotechnology in drug delivery market was valued at US$53.0 billion in 2021 and is projected to grow at a CAGR of 18.7% during the forecast period 2022-2032.

20 June 2022

READ

Industries > Pharma > Global Acute Myeloid Leukaemia Market Forecast to 2029

Back to Pharma Reports

Global Acute Myeloid Leukaemia Market Forecast to 2029

Chemotherapy, Targeted Therapy, Cytarabine, Daunorubicin, Midostaurin, Enasidenib

Download sample pages

Related reports

Top 25 Biosimilar Drug Manufacturers 2019

Biological Drug API Manufacturing Services World Industry and Market Forecast to 2029

Global Diagnostic Imaging Market Forecast 2019-2029

Global Protein Expression Market Forecast to 2029

Global Biosimilars and Follow-On Biologics Market 2019-2029

Next-Generation Biologics Market Forecast to 2029

Global Oncology Pricing, Reimbursement & Market Access 2019-2029

Download sample pages

Share

Connect with us

Latest Pharma news

Visiongain Publishes Precision Medicine Market Report 2022-2032

Visiongain Publishes Biologics Market Report 2022-2032

Visiongain Publishes Liposomal Drug Delivery Devices Market Report 2022-2032

Visiongain Publishes Nanotechnology in Drug Delivery Market Report 2022-2032

Categories

Our Clients